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Objective: Diabetic complications and lipid peroxidation are known to have a close association. Lipid
peroxidation commonly occurs at sites exposed to ischaemia, but distant organs and tissues also get damaged
during ischaemia/reperfusion (I/R). Some of these targets are vital organs, such as the lung, liver, and kidney;
the lung is the most frequently affected. The aim of our study was to investigate the effects of dexmedetomidine
on I/R damage in lung tissue and on the oxidant/anti-oxidant system in diabetic rats.
Material and methods: Diabetes was induced with streptozotocin (55 mg/kg) in 18 Wistar Albino rats, which
were then randomly divided into three groups (diabetes control (DC), diabetes plus ischaemia-reperfusion
(DIR), and diabetes plus dexmedetomidine-ischaemia/reperfusion (DIRD)) after the effects of diabetes were
clearly evident. The rats underwent a left thoracotomy and then ischaemia was produced in the myocardium
muscle by a left anterior descending artery ligation for 30 min in the DIR and DIRD groups. I/Rwas performed
for 120 min. The DIRD group received a single intraperitoneal dose of dexmedetomidine (100 mg/kg); the DIR
group received no dexmedetomidine. Group DC was evaluated as the diabetic control group and also included
six rats (C group) in which diabetes was not induced. These mice underwent only left thoracotomy and were
closed without undergoing myocardial ischaemia. Histopathological changes, activities of catalase (CAT) and
glutathione-S-transferase anti-oxidant enzymes, and malondialdehyde (MDA) levels were evaluated in the lung
tissues of all rats.
Results: Neutrophil infiltration/aggregation was higher in the DIR group than in the C, DC, and DIRD groups
(p0.001, p0.013, and p0.042, respectively). The lung injury score was significantly higher in the DIR
group than in the C and DC groups (pB0.0001 and p0.024, respectively). The levels of MDA were
significantly higher in the DIR group than in the C and DIRD groups. CAT activity was significantly higher in
the DIR group than in the DIRD and C groups.
Conclusion: Our results confirm that dexmedetomidine has protective effects against the lung damage resulting
from I/R in diabetic rats. Future studies conducted to evaluate the effects of the use of dexmedetomidine on
damage to various organs following different I/R durations may help understanding possible protective effects
of dexmedetomidine and underlying mechanisms in tissue damage related to I/R injury.
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M
yocardial tissue ischaemia occurs due to per-
fusion loss, but it also arises in the microcircu-
lation and distant organs because of reactive
oxygen radicals generated during reperfusion and via
the systemic inflammatory response (1, 2). Free oxygen
radicals released from the ischaemic myocardium may
cause damage to many distant organs such as lung, kidney,
intestines, and pancreas. Oxidative stress and lipid perox-
idation play important roles in distant organ damage
after ischaemia/reperfusion (I/R) (3). Lipid peroxidation
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seen in diabetic patients further increases the damage to
distant organs following reperfusion of the myocardium
exposed to ischaemia (4). Among the distant organs, in-
direct damage seen after I/R is defined best in the lung
(5) and is associated with these mechanisms. Therefore,
acute lung injury may indirectly develop during and after
pulmonary oedema.
Dexmedetomidine hydrochloride is an a2 agonist that
has been used for sedation in anaesthesia in intensive
care units (6). Besides its sedative effect, dexmedeto-
midine hydrochloride also has confirmed analgaesic and
anxiolytic properties. Recent studies have shown that
dexmedetomidine decreased the systemic inflammatory
response, inhibited the release of inflammatory cytokines,
and suppressed pulmonary and hepatic inflammation. The
suppressive effects of inflammatory cytokines on tumour
necrosis factor-a (TNF-a), interleukin-1b (IL-1b), IL-6,
and macrophage inflammatory protein-2 (MIP-2) have
been demonstrated; thus, inflammatory cytokine release
is understood to alleviate acute organ damage and reduce
inflammation during sepsis. Animal studies have demon-
strated that dexmedetomidine decreased ischaemic reper-
fusion damage in various organs (intestines, myocardium,
lung, liver, cerebrum, and kidney) (711). Dexmedetomi-
dine alleviates lung damage effectively for the prevention
of I/R damage, as well as for haemorrhagic shock, ventilator-
related lung damage, rats in which pneumoperitoneum
was induced, and pulmonary contusions occurring after
blunt trauma (11). Protective effects of dexmedetomidine
against inflammation secondary to cardiac, renal, hepatic,
testicular, and cerebral IR injury have been described,
but its effects on indirect lung damage developing after
myocardial I/R have yet to be fully clarified. The objec-
tive of this study was to investigate the changes in the
levels of malondialdehyde (MDA) and the activities of
glutathione-S-transferase (GST) and catalase (CAT) anti-
oxidant enzymes, as well as the histopathological features
of lungs as indirectly damaged distant organs.
Material and methods
Animals and experimental protocol
This study was conducted in the GUDAM Laboratory of
Gazi University with the consent of the Experimental
Animals Ethics Committee at Gazi University. All proce-
dures were performed according to the accepted standards
of the Guide for the Care and Use of Laboratory Animals.
The study used 18 male Wistar albino rats, weighing
between 225 and 275 g, raised under the same environ-
mental conditions. For at least 1 week prior to surgery,
the animals were housed in standard cages in a pathogen-
free environment, with free access to food (until 2 h
prior to the anaesthetic procedure) and water and with a
12-h light/dark cycle.
Diabetes was induced by a single intraperitoneal in-
jection of streptozotocin (Sigma Chemical, St. Louis, MO,
USA), at a dose of 55 mg/kg body weight. The blood
glucose levels were measured 72 h and 4 weeks following
this injection. Rats were classified as diabetic if their
fasting blood glucose levels exceeded 250 mg/dl, and only
animals with fasting blood glucose of 250 mg/dl were
included in the diabetic groups (diabetes control (DC),
diabetes plus ischaemia-reperfusion (DIR), and diabetes
plus dexmedetomidine-ischaemia-reperfusion (DIRD)).
Rats were anaesthetised with an intraperitoneal injec-
tion of 100 mg/kg of ketamine. The trachea was cannulated
for artificial respiration. The chest was shaved, and each
animal was fixed in a supine position on the operating
table. The chest was opened by a left thoracotomy followed
by sectioning the fourth and fifth ribs about 2 mm to the
left of the sternum. Positive-pressure artificial respiration
was started immediately with room air, using a volume
of 1.5 ml/100 g body weight at a rate of 60 strokes/min.
Sodium heparin (500 IU/kg) was administered through
the peripheral vein in the tail.
Following left thoracotomy, ischaemia was produced
in the myocardium muscle by a left anterior descending
(LAD) artery ligation for 30 min in the DIR and DIRD
groups (12). Following ischaemia, the LAD ligation was
removed and reperfusion was performed for 120 min. The
DIRD group received a single intraperitoneal dose of
dexmedetomidine (100 mg/kg); the DIR group received no
dexmedetomidine (13). The DC group was evaluated as
the diabetic control group and included six rats (C group)
which were not induced with diabetes. These mice under-
went only left thoracotomy and were closed without un-
dergoing myocardial ischaemia. Activities of CAT and GST
anti-oxidant enzymes and MDA quantities were measured.
Histopathological changes were evaluated in 10 random
samples by microscopic examination of lung sections
stained with haematoxylin and eosin.
Histopathological evaluation of the lung
Lung samples were examined histopathologically by light
microscopy by the same pathologist, who was blinded to
the study. Lung injury in each area was evaluated by
determining the alveolar thickness and neutrophil infil-
tration or aggregation. Each parameter was evaluated as
none (0 point), slight (1 point), moderate (2 points), or
severe (3 points); the two scores were added, and the total
score was interpreted as the lung injury score (14).
Measurements of MDA levels and CAT and GST
activities in lung tissue
The lung tissues were first washed with cold-deionised
water to remove blood contamination and then homo-
genised in a 10-fold volume of physiological saline solution
(0.154 M) using a homogeniser (Heidolph DIAX900) at
3,000 rpm for 3 min. After centrifugation at 10,000g
for 10 min, the clear upper layer was removed and stored
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at 808C until assessment. A supernatant of 10% (w/v)
was used for MDA measurements as described by Van Ye
et al. (15). All procedures were performed at 48C
throughout the experiments.
Part of the homogenate was extracted in an ethanol/
chloroform mixture (5/3: v/v) to remove the lipid fraction,
which interferes with the activity measurements of CAT
and GST enzymes.
After centrifugation at 10,000g for 60 min, the clear
upper layer was removed and used for CAT and GST
analyses as described by Aebi and by Habig (16, 17). The
CAT activity method is based on the measurement of the
absorbance decrease due to H2O2 consumption at 240 nm.
The GST activity method is based on the measurement
of absorbance changes at 340 nm due to formation of a
GSH-CDNB complex. MDA level in lung supernatant
was measured by monitoring the formation of thiobarbi-
turic acid-reactive substances (TBARS) using the method
of Van Ye et al. In brief, 0.1 ml of tissue homogenate
(PBS; 100 mM, pH 6 Na2HPO4/KH2PO4) was treated
with 2 ml of TBATCAHCl reagent (0.2% thiobar-
bituric acid, 0.6 N HCl, and 20% TCA in absolute
ethanol), placed in boiling water for 30 min, cooled, and
centrifuged at room temperature for 10 min. The absor-
bance of the clear supernatant was measured spectro-
photometrically against reference blank at 535 nm, using
1,1,3,3-tetraethoxy propane (TEP) as a standard.
Statistical analysis
The Statistical Package for the Social Sciences program
(SPSS, version 20.0, Chicago, IL, USA) was used for sta-
tistical analysis. The KolmogorovSmirnov test was used
for the comparisons to determine the distribution of
all variable groups. Variations in CAT and GST activi-
ties, MDA levels, and histopathological parameters were
assessed using the KruskalWallis test. A Bonferroni-
adjusted MannWhitney U test was used after a signifi-
cant KruskalWallis finding to determine which group
differs from the others. Histopathological percentage
was analysed with Fisher’ s test and x2 test. Results are
expressed as mean9standard deviation (SD). Statistical
significance was set at a pB0.05.
Results
Comparison of the light microscopy findings for lung
tissue neutrophil infiltration/aggregation revealed a signifi-
cant difference among the groups (p0.006). Neutrophil
infiltration/aggregation was significantly higher in the DIR
group than in the C and DC groups (p0.001 and p0.013,
respectively) (Table 1; Figs. 1 and 2).
Alveolar wall thickening in lung tissue was significantly
higher in the DIR group than in the C, DC, and DIRD
groups (p0.003, p0.003, and p0.016, respectively)
(Table 1; Fig. 1). Alveolar wall thickening was also
significantly higher in the DIR and DIRD groups than
in the C group (p0.003 and p0.007, respectively).
Comparison of lung tissue injury scores determined
from light microscopy findings revealed a significant dif-
ference among the groups (pB0.0001). The lung tissue
injury score was significantly higher in the DIR group
than in the C and DC groups (pB0.0001 and p0.024,
respectively) (Table 1; Fig. 1). In addition, the lung
tissue injury score was significantly higher in the DIR
and DIRD groups than in the C group (p0.003 and
p0.05, respectively).
In addition, percentage of comparison of the light
microscopy findings for lung tissue neutrophil infiltra-
tion/aggregation, alveolar wall thickening, and lung tissue
injury scores revealed a significant difference among the
groups (p0.005, pB0.0001, and p0.001, respectively)
(Table 2).
Comparison of the groups to each other in terms of
lung tissue MDA levels revealed a significant difference
(p0.001). MDA levels were significantly higher in the
DIR group than in the C and DIRD groups (p0.005
and p0.002, respectively) (Table 3). Comparison of
the groups to each other in terms of CAT enzyme activity
also revealed a significant difference (p0.015). CAT en-
zyme activity was significantly higher in the DIR group
than in the C and DIRD groups (p0.002 and p0.012,
respectively) (Table 3).
Table 1. Histopathological findings of the lung tissue
Group C (n6) Group DC (n6) Group DIR (n6) Group DIRD (n6) P
Neutrophil infiltration/aggregation 0.090.0* 0.3390.52* 1.1790.41 0.590.55 0.006
Alveolar wall thickening 0.3390.52* 0.6790.52* 2.6790.52§ 1.6790.52*,§ B0.0001
Score (neutrophil infiltration/
aggregationalveolar wall thickening)
0.3390.52* 1.0090.63* 4.0090.89§ 2.1790.65*,§ B0.0001
Values are mean9SD. C: control; DC: diabetes control; DIR: diabetes plus ischaemia-reperfusion; DIRD: diabetes plus
dexmedetomidine-ischaemia-reperfusion.
Statistical significance was set at pB0.05 for KruskalWallis test. *pB0.05 when compared with Group DIR. §pB0.05 when compared
with Group C.
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When groups were compared with each other in terms
of GST enzyme activity, a significant difference was
observed (pB0.0001). GST enzyme activity was signi-
ficantly higher in the DIR group compared with the
C, DC, and DIRD groups (pB0.0001, pB0.0001, and
pB0.0001, respectively) (Table 3).
Discussion
Damage related to I/R may develop in the lung under
various conditions. It may occur directly due to ischaemia
and subsequent reperfusion, or may arise due to mediators
released into the systemic circulation due to reperfusion
following the occurrence of ischaemia in other distant
organs; numerous human and animal studies have been
conducted on this subject (4, 13, 18). Changes in the micro-
circulation are among the leading causes of the damage
that occurs to lung tissues, but diabetes affects and
damages the microcirculation independently from all known
factors (19). Changes occurring in the microcirculation
may negatively affect the duration of ischaemia and may
cause expansion of the ischaemic area (19, 20). Therefore,
the present study was conducted on diabetic rats.
A number of studies have demonstrated that dexmede-
tomidine has a protective effect against I/R injury in
several organs, including lung, heart, brain, and kidney,
which is thought to be due to its anti-oxidant and anti-
inflammatory properties (2126). Some enzymes function
as intracellular antioxidants against the damage caused
by oxidative stress occurring during I/R. High activities
of these enzymes can be considered as indicators that
cells require protection against inflammation and subse-
quent pulmonary damage. CAT catalyses the destruction
of H2O2 (27), and elevated blood levels of CAT indicate
anti-oxidant activity. MDA is one of the end products
of lipid peroxidation and is considered a marker of cell
wall peroxidation. Plasma and tissue levels of MDA are
accepted as good markers of the oxidative stress and
the systemic response that follows I/R (28). Much more
GST enzyme activity is observed in the liver tissue
compared with lung and heart tissues; nevertheless, high
GST activity can be accepted as a marker of elimination of
metabolites related to peroxidation and mostly indicates
damage caused by reactive oxygen products (29).
We measured CAT and GST enzyme activities and
MDA levels to determine the effects of dexmedetomidine
on the activities of these cellular protective factors. As
a result, levels of tissue MDA, CAT enzyme activity,
and GST enzyme activity were significantly lower in the
Fig. 1. (a) Severe neutrophilic infiltration and increased alveolar wall thickness in the DIR group, HE200. (b) Moderate
neutrophilic infiltration and increased alveolar wall thickness in the DIRD group, HE100. (c) Mild neutrophilic infiltration
and increased alveolar wall thickness in the DC and D groups, HE100. (d) Normal structure lung tissue parenchyma in the
control group, HE200.
Fig. 2. Neutrophil infiltration/aggregation. *pB0.05 when
compared with Group DIR.
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DIRD group when compared with the DIR only group.
These results indicate protective role of dexmedetomidine
against inflammatory processes in alveolar tissue.
Jiang et al. found in their histopathological study that
severe pulmonary damage occurred in the I/R group, whereas
I/R damage was less in rats administered 2.5 mg/kg/h dex-
medetomidine 1 h before I/R (30). Gu et al. also reported that
more pulmonary damage developed in distant organs than in
normal lung tissues following renal I/R and that dexmede-
tomidine decreased that damage (31). The histological re-
sults from that study revealed marked haemorrhage in the
lamina propria, with loss of integrity, increased interstitial
cellularity, and deterioration of alveolar and pulmonary
structures in the group not receiving dexmedetomidine. A
study by Shen et al. evaluated pulmonary histopathology by
semi-quantitative scoring, using pulmonary oedema, exis-
tence of inflammatory cells, existence of alveolar haemor-
rhage, and presence of hyaline membranes and alveolar
atelectasis as criteria (32). Pulmonary damage occurring
following intestinal ischaemic reperfusion was less in the
dexmedetomidine group. A study by Yang et al. investigated
the effects of dexmedetomidine onventilator-induced pulmo-
nary damage and reported lung tissue morphology changes:
lung tissue injury, swelling in the alveolar epithelium, alveolar
wall changes, and infiltration of polymorphonuclear leuko-
cytes (33). In our study, we found histopathological results
resembling those mentioned above. First, alveolar wall thick-
ening in lung tissue was significantly lower in the DIRD
group than in the DIR group. Alveolar wall thickening is a
well-known feature of inflammation triggered by leucocyte
and macrophage accumulation plus perivascular oedema
together with intra-alveolar oedema. Second, although the
extent of neutrophil infiltration/aggregation was indifferent
between the DIR and DIRD groups, the sum of alveolar
wall thickening and neutrophil infiltration/aggregation (total
injury score) was lower in the DIRD group than in the DIR
group. Taken together (histopathological results and tissue
anti-oxidant levels), we can postulate an anti-oxidant and
anti-inflammatory effect of dexmedetomidine on alveolar
tissue during alveolar I/R injury in diabetic rats.










Neutrophil infiltration/aggregation 0 (none) 6 (100) 4 (66.7) 0 (0) 3 (50) 0.005
1 (slight) 0 (0) 2 (33.3) 5 (83.3) 3 (50)
2 (moderate) 0 (0) 0 (0) 1 (16.7) 0 (0)
3 (severe) 0 (0) 0 (0) 0 (0) 0 (0)
Alveolar wall thickening 0 (none) 4 (66.7) 2 (33.3) 0 (0) 0 (0) B0.0001
1 (slight) 2 (33.3) 4 (66.7) 0 (0) 2 (33.3)
2 (moderate) 0 (0) 0 (0) 2 (33.3) 4 (66.7)
3 (severe) 0 (0) 0 (0) 4 (66.7) 0 (0)
Score (neutrophil infiltration/ 0 4 (66.7) 1 (16.7) 0 (0) 0 (0) 0.001
aggregationAlveolar wall thickening) 1 2 (33.3) 4 (66.7) 0 (0) 1 (16.7)
2 0 (0) 1 (16.7) 0 (0) 3 (50)
3 0 (0) 0 (0) 2 (33.3) 2 (33.3)
4 0 (0) 0 (0) 2 (33.3) 0 (0)
5 0 (0) 0 (0) 2 (33.3) 0 (0)
Values are n (%). C: control; DC: diabetes control; DIR: diabetes plus ischaemia-reperfusion; DIRD: diabetes plus dexmedetomidine-
ischaemia-reperfusion.
Statistical significance was set at pB0.05 for x2 test.
Table 3. Oxidant status parameters of rat lung tissue (Mean9SD)
Group C (n6) Group DC (n6) Group DIR (n 6) Group DIRD (n 6) P
MDA (nmol/mg prot) 0.8190.32* 1.2590.39 1.6190.27 0.7390.23* 0.001
GST (IU/mg prot) 1.1590.21* 1.8790.98* 6.6591.63 1.1690.07* B0.0001
CAT (IU/mg prot) 676.709124.82* 936.479267.01 1296.319417.02 810.539159.19* 0.015
Values are mean9SD. C: control; DC: diabetes control; DIR: diabetes plus ischaemia-reperfusion; DIRD: diabetes plus
dexmedetomidine-ischaemia-reperfusion. MDA: malondialdehyde; GST: glutathione-S-transferase; CAT: catalase.
Statistical significance was set at pB0.05 for KruskalWallis test. *pB0.05 when compared with Group DIR.
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Conclusion
Our study shows that dexmedetomidine could provide
lung protection after myocardial I/R; for this reason, dex-
medetomidine has potential value in decreasing lung
injury following myocardial I/R, in addition to its sedative
and analgesic properties. However, further studies are
required on this subject.
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Gülay Kip et al.
6
(page number not for citation purpose)
Citation: Libyan J Med 2015, 10: 27828 - http://dx.doi.org/10.3402/ljm.v10.27828
30. Jiang L, Li L, Shen J, Qi Z, Guo L. Effect of dexmedetomidine
on lung ischemia reperfusion injury. Mol Med Rep. 2014; 9:
41926.
31. Gu J, Chen J, Xia P, Tao G, Zhao H, Ma D. Dexmedetomidine
attenuates remote lung injury induced by renal ischemia
reperfusion in mice. Acta Anaesthesiol Scand. 2011; 55: 12728.
32. Shen J, Fu G, Jiang L, Xu J, Li L, Fu G. Effect of
dexmedetomidine pretreatment on lung injury following intest-
inal ischemia-reperfusion. Exp Ther Med. 2013; 6: 135964.
33. Yang CL, Tsai PS, Huang CJ. Effects of dexmedetomidine on
regulating pulmonary inflammation in a rat model of ventilator-
induced lung injury. Acta Anaesthesiol Taiwan. 2008; 46: 1519.
The effect of dexmedetomidine on lung damage
Citation: Libyan J Med 2015, 10: 27828 - http://dx.doi.org/10.3402/ljm.v10.27828 7
(page number not for citation purpose)
